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Tetrahydrobiopterin-Dependent Monoamine-Neurotransmitter
Deficiency without Hyperphenylalaninemia
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Classic tetrahydrobiopterin (BH4) deficiencies are characterized by hyperphenylalaninemia and deficiency of mono-
amine neurotransmitters. In this article, we report two patients with progressive psychomotor retardation, dystonia,
severe dopamine and serotonin deficiencies (low levels of 5-hydroxyindoleacetic and homovanillic acids), and
abnormal pterin pattern (high levels of biopterin and dihydrobiopterin) in cerebrospinal fluid. Furthermore, they
presented with normal urinary pterins and without hyperphenylalaninemia. Investigation of skin fibroblasts revealed
inactive sepiapterin reductase (SR), the enzyme catalyzing the final two-step reaction in the biosynthesis of BH4.
Mutations in the SPR gene were detected in both patients and their family members. One patient was homozygous
for a TCrCT dinucleotide exchange, predicting a truncated SR (Q119X). The other patient was a compound
heterozygote for a genomic 5-bp deletion (1397–1401delAGAAC) resulting in abolished SPR-gene expression and
an ArG transition leading to an R150G amino acid substitution and to inactive SR as confirmed by recombinant
expression. The absence of hyperphenylalaninemia and the presence of normal urinary pterin metabolites and of
normal SR-like activity in red blood cells may be explained by alternative pathways for the final two-step reaction
of BH4 biosynthesis in peripheral and neuronal tissues. We propose that, for the biosynthesis of BH4 in peripheral
tissues, SR activity may be substituted by aldose reductase (AR), carbonyl reductase (CR), and dihydrofolate
reductase, whereas, in the brain, only AR and CR are fully present. Thus, autosomal recessive SR deficiency leads
to BH4 and to neurotransmitter deficiencies without hyperphenylalaninemia and may not be detected by neonatal
screening for phenylketonuria.
Introduction
Tetrahydrobiopterin (BH4) deficiencies are severe neuro-
logical disorders characterized by hyperphenylalaninemia
and by monoamine-neurotransmitter deficiency and
caused by mutations in the genes encoding the enzymes
responsible for BH4 biosynthesis and regeneration (Blau
et al. 2001). BH4 is an essential cofactor for enzymes such
as nitric oxide synthase, phenylalanine-3-hydroxylase,
and the rate-limiting catecholamine- and serotonin-bio-
synthesis enzymes tyrosine-4-hydroxylase and trypto-
phan-5-hydroxylase. The biosynthesis of BH4 starts from
GTP via reactions catalyzed by the enzymes GTP cyclo-
hydrolase I (GTPCH [E.C.3.5.4.16]), 6-pyruvoyltetrahy-
dropterin (PTP) synthase (PTPS [E.C.4.6.1.10]), and se-
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piapterin reductase (SR [E.C.1.1.1.153]). Alternatively,
the final two-step reduction of the intermediate PTP to
BH4 can be effected by aldose reductase (AR) and car-
bonyl reductase (CR) (fig. 1). Two additional enzymes,
pterin-4a-carbinolamine dehydratase (E.C.4.2.1.96) and
dihydropteridine reductase (DHPR [E.C.1.6.99.7]), are
involved in the regeneration of BH4 from intermediates
formed during the hydroxylation of aromatic amino ac-
ids (Tho¨ny et al. 2000).
Most patients with autosomal recessive BH4 deficien-
cies present with progressive neurological deterioration,
regardless of their different enzyme defects. The clinical
manifestation is variable, but common symptoms are
mental retardation, convulsions, disturbance of tone
and posture, abnormal movements, hypersalivation,
swallowing difficulties, and temperature instability and
oculogyric crises (Blau et al. 1996). These patients can
be detected by neonatal screening for phenylketonuria
(PKU [MIM 261600]), owing to abnormally high levels
of phenylalanine in blood. The autosomal dominant
form of GTPCH deficiency, dopa-responsive dystonia
(DRD [MIM 600225]), however, presents without
hyperphenylalaninemia, and patients with DRD can be
diagnosed only by the typical clinical signs and symp-
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Figure 1 Biosynthesis of tetrahydrobiopterin and proposed alternative routes in SR deficiency (for details, see text)
toms, by responsiveness to L-dopa (Nygaard and Woo-
ten 1998), and by investigation of cerebrospinal fluid
(CSF).
Recently, we investigated production of neopterin and
biopterin in cytokine-stimulated fibroblasts from pa-
tients with different forms of BH4 deficiencies. Further-
more, we measured the activity of all enzymes involved
in BH4 metabolism in normal and stimulated cells. By
this method, we showed that both the classic forms of
BH4 deficiency and DRD can be differentiated in fibro-
blasts (Bonafe´ et al. 2001). In this study, we investigated
fibroblasts from two patients with severe neurotrans-
mitter depletion without hyperphenylalaninemia who
were initially diagnosed with a “central” form of DHPR
deficiency (MIM 261630) (Blau et al. 1998). Pterin me-
tabolites and enzymatic activities revealed SR deficiency,
which was confirmed by DNA mutation analysis. We
thus describe a new autosomal recessive form of BH4
deficiency with monoamine-neurotransmitter depletion
and without hyperphenylalaninemia, and we propose
alternative routes, in different tissues, for the final step
in the BH4-biosynthesis pathway.
Patients and Methods
Patients
The two patients described are registered in the in-
ternational database BIODEF (Blau et al. 1996). Patient
360 (BIODEF) is a 14-year-old adolescent male born of
consanguineous parents of Turkish origin. He presented
with psychomotor retardation, spasticity, dystonia,
microcephaly, and growth retardation (Blau et al. 1998).
Patient 229 (BIODEF) is a 9-year-old boy born of un-
related parents of Turkish origin. He presented with pro-
gressive psychomotor retardation, spasticity, tremor,
ataxia, dystonic posturing and falls (initially misinter-
preted as epileptic seizures), depressive and aggressive
behavior, and oculogyric crises (Blau et al. 1999); there
were also marked diurnal fluctuations. Both patients
were initially classified as having a “central” form of
DHPR deficiency, because of a CSF-pterin pattern typical
of this disorder. Table 1 summarizes the most-important
biochemical findings. Plasma phenylalanine, urinary and
plasma total neopterin and total biopterin, and red
blood cell DHPR activity were all normal. After BH4
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Table 1




Age at diagnosis (years) 10 5 …
Plasma phenylalanine (mmol/liter) !90 !90 26–98
CSFa(nmol/liter):
Total neopterin 28 24 9–30
Total biopterin 83 77 10–44
Dihydrobiopterin 57 42 !14
5HIAA 14 4 88–178
HVA 111 49 144–801
Urine (mmol/mol creatinine):
Total neopterin .65 .78 .2–1.7
Total biopterin .58 .70 .5–2.7
Fibroblasts:
Total neopterin (pmol/mg) 169 238 18–98
Total biopterin (pmol/mg) 29 57 154–303
SR activity (mU/mg) !10 !10 99–185
Red blood cells:
SR activityb (mU/mg) .34 .36 .33–1.86
Genomic DNA 1303–1304TCrCT (homozygous) 1397ArG, 1397–1401delAGAAC Wild type
cDNA 354–355TCrCT 448ArG Wild type
Effect on protein Q119X R150G Wild type
a Source: Blau et al. (1998, 1999). 5HIAA p 5-hydroxyindoleacetic acid; HVA p homovanillic acid.
b Assay is not specific to SR (for details, see text).
administration, both patients responded to the oral load-
ing test with phenylalanine, suggesting reduced phenyl-
alanine hydroxylation in the liver (Blau et al. 1999).
DNA analysis of all coding exons of the QDPR gene
failed to detect any mutation (I. Dianzani and A. Rom-
stad, personal communication). Neurotransmitter-pre-
cursor therapy was started, in patients 229 and 360, at
the ages of 5 years and 10 years, respectively. In both
subjects, administration of 5-hydroxytryptophan re-
sulted in severe vomiting and/or leucopenia, whereas ad-
ministration of L-dopa resulted in clinical improvement.
Selegiline (L-deprenyl) was introduced only in patient
360.
Methods
Study of pterin metabolism in fibroblasts.—Cell cul-
turing, production of neopterin and of biopterin in fibro-
blasts after stimulation with cytokines for 24 h, and SR-
activity measurements in nonstimulated fibroblasts were
performed as described elsewhere (Bonafe´ et al. 2001).
For fibroblast cultures, the appropriate informed consent
was obtained from all subjects.
SR activity in red blood cells.—SR activity in red blood
cells was assayed according to the method described by
Ferre and Naylor (1988), with sepiapterin as a substrate
and under assay conditions essentially the same as those
for the fibroblasts (see the preceding paragraph). The
assay monitors the conversion of sepiapterin to dihydro-
biopterin, which is then measured as the oxidized prod-
uct, biopterin. Because the same reaction can be cata-
lyzed by CR (Park et al. 1991), this assay measures
activities of both SR and CR. Also, substrates used in
the CR assay can be reduced by SR (Katoh and Sueoka
1984).
Mutation analysis.—All oligonucleotide primers were
custom synthesized by Microsynth. For SR cDNA anal-
ysis, total RNA was extracted from skin fibroblasts of
the two patients (RNeasy Mini Kit; Qiagen). On the
basis of the published SR cDNA sequence (GenBank
accession number M76231; Ichinose et al. 1991), a 756-
bp fragment harboring 96% of the coding sequence was
amplified by one-step reverse-transcription PCR (RT-
PCR) (OneStep RT-PCR Kit; Qiagen), by the cDNA-
specific primers SR12 (5′-[8]GCGGGCTGGGGCGTG-
CTGTG-3′) and SR13 (5′-[763]GGGCTCCAGACTTG-
AACTCG-3′) (the nucleotide numbers in square brackets
refer to the published cDNA sequence, and numbering
starts with 1 at adenosine in the ATG-start codon). PCR
amplification was performed under standard conditions,
at an annealing temperature of 56C and in 35 cycles.
To analyze the corresponding SPR gene, genomic DNA
from the two patients was extracted from fibroblasts,
and DNA from their parents was extracted from whole
blood cells by standard procedures (QIAmp DNA Mini
Kit; Qiagen). The three coding exons of SPR were each
amplified at an annealing temperature of 54C and in
35 cycles, by the following primer pairs: SR14 (5′-
[187]CAGCAACCAAGGGAACCAGA-3′) and SR15
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(5′-[933]GCAAGGGGCTCGGGAAAGTT-3′) to yield a
747-bp fragment for exon 1; SR16 (5′-[810]GCAAGTG-
GAGGCGAGGTGTA-3′) and SR17 (5′-[1858]GAGCG-
TCTTCCCCATTTCAC-3′) to yield a 1,049-bp frag-
ment for exon 2; and SR18 (5′-[141]AATAGAAATGG-
GAATGTCAG-3′) and SR19 (5′-[880]GGGATAGAGA-
CACCAATACC-3′) to yield a 740-bp fragment for exon
3 (the nucleotide numbers in square brackets refer to
the deposited genomic DNA sequences) (Ohye et al.
1998; GenBank accession numbers AB017547, for ex-
ons 1 and 2, and AB017548, for exon 3).
The amplification products from genomic DNA and
cDNA were separated on 1% agarose gels, purified
(Concert Gel Extraction Systems; Life Technologies;
Gibco BRL), and directly sequenced using fluorescence-
labeled terminator reagents and an automated se-
quencer (ABI Prism 310, Applied Biosystems). The prim-
ers used for PCR amplification were also used for
sequence analysis, with the addition of the primer pair
SR22 (5′-[1190]GGGAGGGCTGGGGAAGAAGAA-3′)
and SR23 (5′-[1574]AGGACAGGGACGGCAGAC-
TT-3′), which were used, with the primer pair composed
of SR16 and SR17, to sequence the exon 2–specific
fragment.
Recombinant expression of human SR in Escherichia
coli.—To express wild-type and mutant R150G SR pro-
teins in E. coli cells, corresponding cDNA fragments
were cloned into the expression vector pGEMEX-2-
Nde, which contained an isopropyl-2-thio-b-D-galacto-
pyranoside (IPTG)–inducible promoter (Tho¨ny et al.
1994). As described above, RT-PCR was performed
with RNA from wild-type or mutant fibroblasts as tem-




tains a recognition site for NdeI, and SR21 contains a
recognition site for BamHI (both underlined). The 0.8-
kb PCR product was gel purified and ligated into theNdeI
and BamHI sites of pGEMEX-2-Nde, to generate plas-
mids pHSR9 and pHSR10, which harbor wild-type and
mutant R150G SR proteins, respectively. Expression of
SR proteins was achieved, in E. coli BL-21 cells (Pro-
mega), by standard induction with IPTG, according to a
protocol recommended by New England Biolabs.
Escherichia coli harboring pHSR9 with wild-type SR,
harboring pHSR10 with R150G SR, or transformed
with the vector alone (pGEMEX control) were used for
expression studies. Cells from 500-ml cultures were har-
vested by centrifugation, resuspended in 2 ml of ice-cold
lysis buffer containing 50 mM potassium phosphate (pH
6.4) and 0.4 mg of lysozyme/ml, frozen in liquid nitro-
gen, lysed by thawing at 8C, and centrifuged at 4C for
20 min at 2,000 g in a SS34 rotor (Sorvall). To obtain
“clear lysates,” supernatants were filtered at 4C
through a Sephadex G50 Nick spin column (Pharmacia)
and were used for protein determination (Bio-Rad), en-
zyme-activity measurement, and western blot analysis.
To measure enzyme activity, 1 mg, 5 mg, and 10 mg of
each clear lysate was incubated in a reaction mixture
containing 0.1 M potassium phosphate, pH 6.4, 0.25
mM reduced nicotinamide adenine dinucleotide phos-
phate (NADPH), and 0.125 mM sepiapterin, according
to assay conditions described elsewhere (Bonafe´ et al.
2001). After 30 min of incubation, the product, 7,8-
dihydrobiopterin, was oxidized and measured as biop-
terin metabolite, in a high-performance liquid chroma-
tography (HPLC) system with fluorescence detection
(Curtius et al. 1991). One unit of SR activity is defined
as the amount that catalyzes the production, from the
sepiapterin substrate, of 1 mmol of biopterin/min.
For western blot analysis, electrophoresis through
12.5%-SDS–polyacrylamide gel was performed accord-
ing to the method of Laemmli (1970), with a prestained
SDS-PAGE low-range protein standard from Bio-Rad.
Proteins were blotted onto nitrocellulose sheets (Bio-
Rad). As a first antibody, the rabbit anti–mouse SR
antibody (provided by Y. S. Park) was applied in a
1:25,000 dilution. As a second antibody, a commercially
available goat anti–rabbit IgG alkaline phosphatase con-
jugate from Bio-Rad was employed. Immunostaining
was performed by the colorimetric method for alkaline
phosphatase, by use of NBT/BCIP solution (Roche).
Results
SR Deficiency Revealed by Metabolic and Enzymatic
Studies of Primary Skin Fibroblasts
On the basis of our recent observation that the mo-
lecular basis of the various BH4 disorders can be dif-
ferentiated by analysis of primary patients’ fibroblasts
(Bonafe´ et al. 2001), we examined cytokine-stimulated
cells for pterin metabolites and/or nonstimulated cells
for BH4-enzymatic activities. Cultured skin fibroblasts
from the two patients presented here were stimulated
with cytokines for 24 h and revealed elevated neopterin
production and low biopterin production, in both cases
(table 1). These findings suggested an enzymatic block
in the biosynthesis of BH4. Moreover, the pattern was
similar to that found in patients with PTPS deficiency
(MIM 261640); however, the PTPS activity was essen-
tially normal when measured in fibroblasts from both
patients (0.3 and 0.6 mU/mg; control value 0.4–1.6 mU/
mg). The GTPCH and DHPR activities in these fibro-
blasts were also in the normal range (data not shown).
In contrast, when we assayed SR under standard con-
ditions with sepiapterin as substrate, activity was below
detection level in fibroblasts from either patient (!10 mU/
mg; control value 99–188 mU/mg), and, when we mea-
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Figure 2 A, Mutations in SPR, in patient 360 and in his father.
B, Mutations in SPR and SR cDNA, in patient 229 and in his parents.
sured SR in red blood cells, activity was in the low-
normal range (table 1). This suggested a primary defect
in the BH4-biosynthetic enzyme SR.
Detection of DNA Mutations in Human SPR
Next, we examined both the SR cDNA and all three
exons of the corresponding SPR gene, by PCR ampli-
fication and direct DNA sequencing. Analysis of patient
360 revealed, in exon 2, a homozygous TCrCT dinu-
cleotide transition at cDNA position 354–355 and at
genomic DNA position 1303–1304 (fig. 2A). This
exchange predicted the mutant allele Q119X with a pre-
mature stop codon at amino position 119. Heterozy-
gosity could be confirmed in at least the father’s genomic
DNA, whereas the mother’s DNA was not available.
In patient 229, cDNA sequencing of the RT-PCR
product exhibited a homozygous ArG missense mu-
tation at position 448, predicting the amino acid
exchange R150G (fig. 2B). Genomic DNA analysis re-
vealed compound heterozygosity in the proband, with
one allele carrying the corresponding ArG nucleotide
exchange at position 1397 in exon 2, as found in the
cDNA. In addition, exon 2 contained a second alter-
ation, a 5-bp deletion spanning nucleotide position
1397–1401 (allele 1397–1401delAGAAC). This dele-
tion predicted a frameshift after triplet Asn149, leading
to a subsequent stop codon at position 152 and, thus,
because the cDNA of this allele was not amplifiable
from the patient’s fibroblasts, to mRNA degradation.
Analysis of genomic DNA of the parents showed that
the mother was heterozygous for the 1397ArG tran-
sition, leading to the mutant allele R150G, and that
the father was heterozygous for the mutant allele
1397–1401delAGAAC.
Recombinant Expression of Mutant R150G and Wild-
Type SR Alleles in E. coli
To verify the effect, at the protein level, of the iden-
tified mutant allele R150G, we assayed wild-type and
R150G SR proteins as recombinant proteins in E. coli.
The mutant allele Q119X was not tested, because ∼55%
of the predicted SR was deleted. SR activities in bacterial
lysate of the clones harboring wild-type and R150G SR
proteins are represented in figure 3A. The specific activ-
ity of wild-type SR was 6.2 U/mg, whereas the negative
control (i.e., bacteria harboring the pGEMEX-expres-
sion vector without SR cDNA) showed background SR
activity (0.14 U/mg) that probably corresponds to the
CR activity. Lysate containing the mutant R150G SR
showed a specific activity similar to that of the negative
control (0.13 U/mg). Expression of SR proteins in bac-
terial cells was verified by western blot analysis, showing
a single immunoreactive band for the SR monomer in
lysates from both wild-type and mutant R150G SR pro-
teins but not for that in lysate from the pGEMEX control
(fig. 3B).
Discussion
The first two cases of SR deficiency described in this
article were distinct from other cases of autosomal re-
cessive forms of BH4 deficiency in that they presented
without hyperphenylalaninemia and thus cannot be de-
tected by the neonatal screening programs for PKU. SR
deficiency becomes the fourth form of BH4 deficiency
to be associated with disturbance in biogenic amine
metabolism. The two defects in the biosynthesis of
BH4—GTPCH and PTPS deficiencies—aswell as a defect
in its regeneration—DHPR deficiency—are character-
ized by deficiency of catecholamines and of serotonin
(Blau et al. 2001). They are all autosomal recessively
inherited and present with hyperphenylalaninemia, in
contrast to the autosomal dominant form of GTPCH
deficiency (DRD), which is characterized by normal
plasma phenylalanine levels. SR deficiency and DRD can
be diagnosed only by investigation of CSF metabolites,
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Figure 3 Recombinant expression of wild-type and mutant R150G SR proteins in bacterial cells. A, SR activity assayed by determination
of biopterin production with sepiapterin as substrate and with different amounts of soluble-protein extracts from E. coli expressing either the
wild type, R150G, or no SR (vector control) from the expression vector pGEMEX. B, Western blot analysis using the same extracts as in panel
A. Each lane contains 0.05 mg of total protein, and cross-reactive material was detected by use of a rabbit anti–mouse SR antibody (arrow).
Note that, although the human recombinant SR is a 28-kD monomer, it runs at ∼34 kD in the 12.5% SDS-PAGE with the molecular-weight
standard here used.
in conjunction with the study of biopterin metabolism
and enzymatic measurements in cultured skin fibro-
blasts. When BH4 biosynthesis in fibroblasts from pa-
tients with BH4 deficiency is induced, for 24 h, with
tumor-necrosis factor–a and interferon-g, pterin pat-
terns characteristic of the different BH4 disorders are
generated (Bonafe´ et al. 2001). Fibroblasts from patients
with autosomal recessive GTPCH deficiency and DRD
produce low amounts of neopterin and biopterin. On
the other hand, those from patients with PTPS deficiency
produce high amounts of neopterin and almost no biop-
terin. This pattern of high neopterin and low biopterin
was also found in our two patients with SR deficiency,
indicating a defect in the biosynthesis of BH4 (table 1).
The absence of SR activity in unstimulated fibroblasts,
in conjunction with the normal PTPS activity, confirmed
the diagnosis. Furthermore, the homozygous mutant al-
lele detected in patient 360, Q119X, although expressed
at the mRNA level, is certainly a null allele, because it
predicts an early stop codon at ∼45% of the normal
polypeptide. The deletion detected in one allele of SPR
in patient 229, 1397–1401delAGAAC, leads to aberrant
gene expression and mRNA degradation. The second
mutant allele, R150G, which is at the same site as the
other mutant allele, leads to a completely inactive mu-
tant protein, as confirmed by recombinant expression in
bacterial cells.
For many years, there has been speculation as to why
no patients with SR deficiency have been detected. It
has been proposed that such a deficiency may be either
fatal in utero or possibly compensated by the activity
of other reductase(s). As shown in this article, neither
proposition obtains, and alternative reductases replac-
ing absent SR activity, at least in peripheral tissues, may
be responsible for the phenotype (see below). SR is an
enzyme catalyzing the NADPH-dependent two-step re-
duction of PTP to BH4 (fig. 1). On the basis of kinetic,
crystallographic, and nuclear magnetic-resonance stud-
ies, the initial step is the reduction at the C-1’-oxo side-
chain of PTP, resulting in the formation of 1’-hydroxy-
2’-oxopropyl-tetrahydropterin (2’-oxo-TP). Internal
rearrangement of the oxo group via side-chain iso-
merization leads to 1’-oxo-2’-hydroxypropyl-tetra-
hydropterin (1’-oxo-TP [6-lactoyl-tetrahydropterin])
(Auerbach et al. 1997). Subsequently, 1’-oxo-TP is re-
duced to BH4 (fig. 1, pathway A). In contrast, Katoh
and Sueoka (1987) have suggested that SR catalyzes the
isomerization of 1’-oxo-TP to 2’-oxo-TP and that iso-
merase function can be further stimulated by NADPH
or the oxidized form of nicotinamide adenine dinucleo-
tide phosphate (Katoh and Sueoka 1988). However,
Smith (1987) has demonstrated that rat erythrocyte SR
catalyzes tetrahydropterin substrates at the relative ve-
locity of sepiapterinr1’-oxo-TPrPTPr2’-oxo-TP and
that the 1’-oxo position of PTP is reduced first. Thus,
pathway A in figure 1 seems to be involved in de novo
biosynthesis of BH4.
SR is a homodimeric protein belonging to the family
of short-chain dehydrogenases/reductases and is inhib-
ited by N-acetyl derivatives of both serotonin and do-
pamine (Smith et al. 1992). Although SR was thought
to be specific for the 1’-oxo group of sepiapterin and
PTP, it was well documented that for that group it has
a broad substrate specificity to carbonyl compounds and
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thus can reduce many “typical” aldo-keto reductase
substrates, such as p-nitrobenzaldehyde and 9,10-phen-
anthrenequinone (Katoh and Sueoka 1984, 1989;
Sueoka and Katoh 1985). Both mouse and human SPR
genes span a region of 4–5 kb, and the reading frames
are split into three exons (Ota et al. 1995; Ohye et al.
1998; Lee et al. 1999). No alternative splice variants
have been observed, and, except for the horse liver en-
zyme (Katoh 1971), not much is known about the ex-
pression and regulation of mammalian SR. The enzyme
has been purified from and characterized in rat eryth-
rocytes (Sueoka and Katoh 1982; Oyama et al. 1990),
rat liver (Smith 1987; Citron et al. 1990), silkworm
(Iino et al. 1992), Chlorobium tepidum (Cho et al.
1999),Dictyostelium discoideum (Kim et al. 2000), and
Drosophila melanogaster (Primus and Brown 1994;
Ruiz-Vazquez et al. 1996; Seong et al. 2000).
In conjunction with two other NADPH-dependent
reductases, SR can produce BH4 from PTP, without
isomerase reaction (Milstien and Kaufman 1986; Levine
et al. 1990). Although it has been shown that SR reduces
1’-oxo-TP to BH4, neither SR inhibitors nor SR anti-
bodies were able to inhibit BH4 production, indicating
that SR alone is not responsible for the synthesis of 1’-
oxo-TP. The enzyme catalyzing this step was later iden-
tified as AR (Milstien and Kaufman 1989; Steinerstauch
et al. 1989). By use of antibodies specific to AR, BH4
biosynthesis was inhibited to ∼60% in crude rat-brain
extracts, suggesting both that the reaction sequence cat-
alyzed by AR accounts for approximately half of BH4
biosynthesis flux in rat brain and that reduction of 1’-
and 2’-oxo groups proceeds at approximately equal
rates (Milstien and Kaufman 1989). AR, in addition to
converting PTP to 1’-oxo-TP, also catalyzes the reduc-
tion of 2’-oxo-TP to BH4 (Park et al. 1991). Thus, in
the presence of CR (Wermuth 1982), an alternative
pathway converting PTP to BH4 in the absence of SR
could be functional in vivo. CR can reduce PTP both
to 1’-oxo-TP and to 2’-oxo-TP; however, the rate of
production is much more preferable for the 1’-oxo in-
termediate (Park et al. 1991).
Park et al. (1991) have proposed that, in the case of
complete SR deficiency, BH4 could be synthesized only
by the concerted action of both AR and CR. Our data
indicate that this may be true for some peripheral tissues
but not for the brain. Expression of these two reductases
is shown to be different in different tissues (Wermuth
1985; Wirth and Wermuth 1985; Forrest and Gonzalez
2000), and our results on fibroblasts from patients with
SR deficiency suggest that CR is not fully active in hu-
man skin fibroblasts. This suggestion is supported by
the fact that, in fibroblasts from patients with SR de-
ficiency, we found high neopterin production and no
biopterin production, after stimulation with cytokines
(table 1). Obviously, PTP either is not reduced to the
1’- and 2’-oxo intermediates or is first reduced to 1’-
oxo-TP and subsequently is converted nonenzymatically
to sepiapterin. In the absence of SR and CR, sepiapterin
cannot be further reduced to dihydrobiopterin (fig. 1,
pathway D). Furthermore, one can speculate that se-
piapterin or one of its degradation products may inhibit
PTPS, resulting in accumulation of neopterin. Because
sepiapterin, used as a substrate in the SR assay, has been
shown to be a substrate also for CR (Park et al. 1991),
we conclude either that CR is not expressed in skin
fibroblasts or that its expression therein is very low.
In mammalian peripheral tissue, such as liver, kidney,
or small intestine, both reductases are active, and, in
the case of SR deficiency, BH4 is synthesized through
the salvage pathway (fig. 1, pathway C). Sepiapterin
formed nonenzymatically from 1’-oxo-TP is, in periph-
eral tissue, reduced to dihydrobiopterin by CR. The final
reduction to BH4 is catalyzed by the enzyme dihydro-
folate reductase (DHFR). Alternatively, a small portion
of BH4 can be synthesized from PTP by the concerted
action of CR and AR, via 2’-oxo-TP. A similar, alter-
native pathway involving two CRs (CR I and CR II)
has been described in the lemon mutant silkworm (Iino
et al. 2000). The normal activity of SR that wemeasured
in the red blood cells of our patients (table 1) is most
probably due to CR activity, which also converts se-
piapterin to dihydrobiopterin (Park et al. 1991). In our
patients, biosynthesis of BH4 was obviously sufficient,
under physiologic conditions, for the hepatic hydrox-
ylation of phenalalanine to tyrosine. Urinary neopterin
and biopterin (table 1) and plasma neopterin and biop-
terin (data not shown) were normal, and blood phe-
nylalanine levels were never elevated. However, on
challenge with phenylalanine the intracellular BH4 con-
centrations may be not sufficient for normal function
of the phenylalanine-hydroxylating system. This was
documented, in both patients, by an abnormal phenyl-
alanine–loading test, which was corrected by preloading
with BH4 (Blau et al. 1999).
Although human brain contains large amounts of AR
(Wermuth et al. 1982) and CR (Wermuth 1981), the
activity of DHFR is ∼10# lower in the brain than in
the liver (Ludwig et al. 1987), and it is ∼2,000# lower
than that of DHPR (Kaufman 1991). Thus, sepiapterin
is reduced to dihydrobiopterin by CR but cannot be
further reduced to BH4, owing to low DHFR activity
(fig. 1, pathway B). This pathway would explain our
finding of high concentrations of total biopterin and
dihydrobiopterin in CSF of patients with SR deficiency
(table 1). Sepiapterin, another potential metabolite that
may also accumulate in patients with SR deficiency, is
a yellow-fluorescent compound and cannot be detected
in our HPLC system for blue-fluorescent neopterin and
biopterin.
In conclusion, we have described the first patients in
276 Am. J. Hum. Genet. 69:269–277, 2001
whom a new inborn error of BH4 metabolism causes
severe monoamine-neurotransmitter deficiency without
hyperphenylalaninemia. We have also proposed the
metabolic routes, in different tissues, for BH4. The exact
mechanisms of action of CR and AR need to be further
elucidated.
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